Enliven Therapeutics, Inc. (ELVN)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Enliven Therapeutics, Inc. (ELVN) Discusses Updated Phase 1 ENABLE Trial Data for ELVN-001 in Previously Treated Chronic Myeloid Leukemia Transcript
Enliven Therapeutics, Inc. (ELVN) Discusses Updated Phase 1 ENABLE Trial Data for ELVN-001 in Previously Treated Chronic Myeloid Leukemia Transcript
Enliven Therapeutics Chief Scientific Officer Sells ELVN 20K Shares Worth Over $500k
Enliven Therapeutics' Chief Scientific Officer sold 20,000 indirect shares for a total of approximately $535,100 on Jan. 20, 2026, at a weighted average price of around $26.75 per share. The sale represented 2.61% of the executive's holdings, reducing his trust's position from 765,188 to 745,188 shares as reported in the SEC Form 4.
Wall Street Analysts Believe Enliven Therapeutics, Inc. (ELVN) Could Rally 101.26%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 101.3% in Enliven Therapeutics, Inc. (ELVN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Enliven Therapeutics, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 20 | $466.37 | $1,038.6 | $572.23 | 122.7% |
| BG Bart Gancher Intech Investment Management LLC | 10,608 | $211,999.98 | $549,533.65 | $337,533.67 | 159.21% |
 John H. Burbank III Passport Capital LLC | 905,191 | $29.28M | $46.89M | $17.62M | 60.18% |
 Joseph Castro Nuveen LLC | 105,883 | $2.11M | $5.55M | $3.44M | 163.31% |
| PK Parth Karia Capricorn Fund Managers Ltd. | 369,400 | $14.48M | $19.49M | $5.01M | 34.58% |
Enliven Therapeutics, Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Salim Syed Mizuho | 582.14 | $21,696.41 | $30,946.56 | $9,250.15 | 42.63% |
Enliven Therapeutics, Inc. (ELVN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Enliven Therapeutics, Inc. ever had a stock split?
Enliven Therapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Richard A. Fair CEO | NASDAQ (NGS) Exchange | 29337E102 CUSIP |
| US Country | 61 Employees | - Last Dividend | 24 Feb 2023 Last Split | 12 Mar 2020 IPO Date |
Overview
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is distinguished by its dedicated pursuit of creating innovative small molecule inhibitors aimed at contributing significantly to cancer treatment. With its central operations based in Boulder, Colorado, Enliven Therapeutics has embarked on a mission to transform the therapeutic landscape for patients bearing the burden of cancer. Through its focused research and development efforts, the company is at the forefront of advancing potential treatment options into clinical evaluation, demonstrating its commitment to addressing the unmet needs within the oncology domain.
Products and Services
Enliven Therapeutics, Inc. is progressively shaping the field of oncology with its notable product candidates, each tailored to target specific cancer types with precision. The following are the cornerstone developments in their portfolio:
- ELVN-001: This pioneering therapy is currently under assessment in a Phase 1 clinical trial, designed to offer a new horizon of treatment for adults diagnosed with chronic myeloid leukemia (CML). ELVN-001 represents Enliven Therapeutics' commitment to tackling hematologic malignancies with novel, targeted therapeutic options.
- ELVN-002: In a stride towards addressing solid tumors, ELVN-002 is another vital component of the company's innovative pipeline. Undergoing a Phase 1 clinical trial in adults, this molecule is particularly focused on solid tumors that present HER2 alterations. This aligns with the company's strategy to expand its therapeutic reach by developing targeted treatments for a broader spectrum of cancers.
